腹水对卵巢癌患者六甲蜜胺及其N-去甲基代谢产物药代动力学的影响。 - Suppr

Suppr

超能文献

Influence of ascites on the pharmacokinetics of hexamethylmelamine and N-demethylated metabolites in ovarian cancer patients.

作者信息

D'Incalci M, Beggiolin G, Sessa C, Mangioni C

出版信息

Eur J Cancer Clin Oncol. 1981 Dec;17(12):1331-5. doi: 10.1016/0014-2964(81)90016-5.

DOI:10.1016/0014-2964(81)90016-5

PMID:6802647

Abstract

摘要

相似文献

Influence of ascites on the pharmacokinetics of hexamethylmelamine and N-demethylated metabolites in ovarian cancer patients.腹水对卵巢癌患者六甲蜜胺及其N-去甲基代谢产物药代动力学的影响。

Eur J Cancer Clin Oncol. 1981 Dec;17(12):1331-5. doi: 10.1016/0014-2964(81)90016-5.

Hexamethylmelamine distribution in patients with ovarian and other pelvic cancers.六甲蜜胺在卵巢癌及其他盆腔癌患者中的分布情况。

Cancer Treat Rep. 1982 Feb;66(2):231-5.

In vivo and in vitro irreversible binding of hexamethylmelamine to liver and ovarian tumor macromolecules of mice.六甲蜜胺在体内和体外与小鼠肝脏及卵巢肿瘤大分子的不可逆结合。

Biochem Pharmacol. 1981 May 15;30(10):1151-4. doi: 10.1016/0006-2952(81)90458-5.

Pharmacokinetics of hexamethylmelamine and pentamethylmelamine in mice.六甲蜜胺和五甲蜜胺在小鼠体内的药代动力学

Cancer Treat Rep. 1981 Jul-Aug;65(7-8):669-72.

Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma.六甲蜜胺在荷卵巢癌小鼠体内的分布、代谢及不可逆结合

Cancer Chemother Pharmacol. 1983;11(1):51-5. doi: 10.1007/BF00257418.

Pharmacokinetics and metabolism of hexamethylmelamine in mice after IP administration.腹腔注射给药后六甲基三聚氰胺在小鼠体内的药代动力学和代谢情况。

Cancer Chemother Pharmacol. 1986;18(3):226-30. doi: 10.1007/BF00273391.

Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.六甲蜜胺和五甲蜜胺在携带M5076/73A卵巢癌小鼠体内的组织分布

Cancer Treat Rep. 1982 Jan;66(1):127-33.

Cerebrospinal fluid levels of hexamethylmelamine and N-demethylated metabolites.

Cancer Treat Rep. 1981 Mar-Apr;65(3-4):350-1.

Dose-dependent pharmacokinetics of PMM in the rat.大鼠体内PMM的剂量依赖性药代动力学

Cancer Chemother Pharmacol. 1981;5(3):201-3. doi: 10.1007/BF00258481.

Hexamethylmelamine tissue concentrations in pelvic cancer patients.盆腔癌患者体内的六甲蜜胺组织浓度。

Ther Drug Monit. 1980;2(2):187-8. doi: 10.1097/00007691-198004000-00013.

引用本文的文献

Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research.身体成分是抗癌药物药代动力学中的一个重要变量吗？综述及进一步研究建议。

Cancer Chemother Pharmacol. 1994;34(1):3-13. doi: 10.1007/BF00686105.

Clinical pharmacokinetics of altretamine.

Clin Pharmacokinet. 1995 Jun;28(6):439-48. doi: 10.2165/00003088-199528060-00002.

Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.六甲蜜胺。对其药效学和药代动力学特性以及在癌症化疗中的治疗潜力的综述。

Drugs. 1995 Jun;49(6):932-53. doi: 10.2165/00003495-199549060-00007.

In vitro evaluation of anticancer drugs in relation to development of drug resistance in the human tumor clonogenic assay.在人肿瘤克隆形成试验中，抗癌药物与耐药性发展相关的体外评估

Cancer Chemother Pharmacol. 1985;15(3):208-13. doi: 10.1007/BF00263887.

N-methyl antitumour agents. A distinct class of anticancer drugs?N-甲基抗肿瘤药物。一类独特的抗癌药物？

Cancer Chemother Pharmacol. 1987;19(2):91-102. doi: 10.1007/BF00254559.

Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients.体重对乳腺癌患者环磷酰胺药代动力学的影响。

Cancer Chemother Pharmacol. 1987;20(3):219-22. doi: 10.1007/BF00570489.

The bioavailability of three altretamine formulations.三种六甲蜜胺制剂的生物利用度。

Pharm Weekbl Sci. 1989 Dec 15;11(6):218-23. doi: 10.1007/BF01959414.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验